Yu Wenyu, Eram Mohammad S, Hajian Taraneh, Szykowska Aleksandra, Burgess-Brown Nicola, Vedadi Masoud, Brown Peter J
Structural Genomics Consortium, University of Toronto, 101 College Street, Toronto, Ontario M5G 1L7, Canada.
Structural Genomics Consortium, University of Oxford, Oxford OX3 7DQ, UK.
Anal Biochem. 2014 Oct 15;463:54-60. doi: 10.1016/j.ab.2014.06.023. Epub 2014 Jul 8.
Covalent modifications, such as methylation and demethylation of lysine residues in histones, play important roles in chromatin dynamics and the regulation of gene expression. The lysine demethylases (KDMs) catalyze the demethylation of lysine residues on histone tails and are associated with diverse human diseases, including cancer, and are therefore proposed as targets for the therapeutic modulation of gene transcription. High-throughput assays have been developed to find inhibitors of KDMs, most of which are fluorescence-based assays. Here we report the development of a coupled scintillation proximity assay (SPA) for 3 KDMs: KDM1A (LSD1), KDM3A (JMJD1A), and KDM4A (JMJD2A). In this assay methylated peptides are first demethylated by a KDM, and a protein methyltransferase (PMT) is added to methylate the resulting peptide with tritiated S-(5'-adenosyl)-l-methionine. The enzyme activities were optimized and kinetic parameters were determined. These robust coupled assays are suitable for screening KDMs in 384-well format (Z' factors of 0.70-0.80), facilitating discovery of inhibitors in the quest for cancer therapeutics.
共价修饰,如组蛋白中赖氨酸残基的甲基化和去甲基化,在染色质动态变化和基因表达调控中发挥着重要作用。赖氨酸去甲基化酶(KDMs)催化组蛋白尾部赖氨酸残基的去甲基化,与包括癌症在内的多种人类疾病相关,因此被提议作为基因转录治疗调控的靶点。已经开发出高通量检测方法来寻找KDMs的抑制剂,其中大多数是基于荧光的检测方法。在此,我们报告了一种针对3种KDMs(KDM1A(LSD1)、KDM3A(JMJD1A)和KDM4A(JMJD2A))的偶联闪烁邻近分析(SPA)的开发。在该分析中,甲基化肽首先被一种KDM去甲基化,然后加入一种蛋白质甲基转移酶(PMT),用氚标记的S-(5'-腺苷基)-L-甲硫氨酸使所得肽甲基化。优化了酶活性并确定了动力学参数。这些稳健的偶联分析适用于以384孔板形式筛选KDMs(Z'因子为0.70 - 0.80),有助于在寻找癌症治疗药物的过程中发现抑制剂。